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Hypoxia is a well-characterized driver of aggressive
cancer phenotypes, including metastasis. Accumulating
evidence suggests that, in addition to having local
effects, the consequences of tumour hypoxia can be
systemic, leading to the formation of pre-metastatic
niches that can later foster metastatic colonization in
distant organs. Recent findings have demonstrated
that such niches can also form in the bone, possibly
revealing new avenues for therapeutic intervention.sponse to hypoxia, leading to formation of osteolyticCancer metastasis is a complex process that consists of a
series of biological phenomena that eventually leads to
the formation of secondary tumours in distant organs.
Even though often pictured as an orderly cascade of
events akin to organismal development, at the cellular
level metastatic tumours emerge from a disorderly
process whereby the dissemination of millions of cells
can eventually lead to the development of only few sec-
ondary tumours [1]. Yet different tumour types have
tendencies to colonize specific organs, suggesting that
underneath the chaos there are principles of order. One
such principle is that metastases need a fertile soil, that
is, a hospitable microenvironment that supports cancer
cells at the early steps of metastatic colonization [2].
The molecular definition of a fertile metastatic soil re-
mains in most cases elusive. It could consist of stem cell
or other niches that provide cancer cells with the re-
quired survival signals in a tissue-specific manner [3].
However, it is clear that beyond pre-existing microenvi-
ronments, cancer cells also need to alter their molecular
surroundings in order to metastasize [4]. This can be
achieved through local cancer cell effects on their imme-
diate microenvironment, but also via systemic effects
that modulate the molecular milieu in distant organs,
resulting in the formation of pre-metastatic niches in
which the efficiency of metastatic colonization is en-
hanced. Pre-metastatic niches have been described inCorrespondence: sv358@mrc-cu.cam.ac.uk
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other soft tissues, and they are often characterized by
the involvement of various immune cell types [5]. How
and when to therapeutically target the many forms of
cancer cell-niche interactions at different steps of meta-
static cancer progression remain critical open questions.
In a recent study, Cox and colleagues [6] add a new
chapter to our understanding of metastatic niches by
demonstrating that oestrogen receptor-negative (ER–)
breast cancer cells with increased potential to form bone
metastases secrete the enzyme lysyl oxidase (LOX) in re-
bone alterations already before cancer cells reach the
bone. Administering cancer cell-conditioned media was
sufficient for the induction of osteolysis, and this en-
hanced bone colonization in a LOX-dependent manner.
Finally, as bisphosphonate treatment is a well-
established strategy to fight osteoporosis, that is, reduced
bone density, the authors show that bisphosphonates
can also reverse the formation of osteolytic pre-
metastatic niches and bone metastases in their model
systems.
The pathobiology of osteolytic bone metastases has
been widely studied, revealing a central role for the
RANKL-RANK system that controls osteoclast matur-
ation [7]. Specifically, various tumour cell-derived fac-
tors, such as interleukin 6 and PTHrP (parathyroid
hormone-related protein), induce RANKL expression in
osteoblasts, resulting in RANK-mediated activation of
osteoclasts and consequent bone resorption. This in turn
releases growth and other factors from the bone matrix,
stimulating the cancer cells to produce more factors that
further stimulate osteoclasts. Interestingly, the results by
Cox and colleagues now suggest that this osteolytic vi-
cious cycle may be kick-started already before cancer
cells arrive and that this can be independent of RANKL.
The authors show that recombinant LOX is able to acti-
vate the transcription factor NFATC1 (nuclear factor of
activated T-cells, cytoplasmic 1), a key driver of osteoclast
maturation, but the molecular pathway through which the
extracellular enzyme LOX transmits a nuclear signal was
not dissected in detail.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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sets, Cox and colleagues focus on ER– breast cancer in
their experimental work. The data suggest, however, that
many ER+ breast cancers also express high levels of
LOX, even though this is not associated with bone me-
tastases. Given the tendency of ER+ breast cancers to
metastasize to the bone [8], it would be interesting and
clinically relevant to know whether ER+ and ER– breast
cancer cells use different molecular mechanisms to in-
duce osteolysis.
A conclusion highlighted by Cox and colleagues is that
LOX expression in ER– breast cancer could be a useful
biomarker for increased bone metastasis risk as well as
for the identification of patients for bisphosphonate
treatment in the adjuvant setting. The use of bispho-
sphonates in breast cancer patients has a long history,
but the results have been inconclusive [9, 10]. Moreover,
it is not clear how much of the potential benefit comes
from actual antitumour effects and how much is related
to a reduction in fractures and consequent mortality [9].
From a biological perspective, the results by Cox and
colleagues are exciting and they give novel insight into
the molecular mechanisms of bone metastasis. From a
clinical perspective, however, it is not clear how target-
ing the pre-metastatic niche could be achieved in prac-
tice. Cancer cells have often already disseminated at the
time of diagnosis. Targeting niche interactions that
support developing bone metastases could therefore be
a more efficient way forward.
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